Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to determine the effect on fasting glucose levels, and safety, of increasing doses of GK [glucokinase] activator(2) [RO 4389620] in patients with type 2 diabetes not optimally controlled with one previous oral antihyperglycemic agent

Trial Profile

An open label study to determine the effect on fasting glucose levels, and safety, of increasing doses of GK [glucokinase] activator(2) [RO 4389620] in patients with type 2 diabetes not optimally controlled with one previous oral antihyperglycemic agent

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piragliatin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 23 Feb 2010 Actual initiation date (Jul 2006) added from Roche record.
  • 18 Jun 2007 Status changed from in progress to completed.
  • 02 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top